在接受艾米齐祖马布预防的患者中活性型前列红素复合物缩物:从证据到临床实践
Robert F Sidonio1, Guy Young2, Carmen Escuriola Ettingshausen3
1Hemophilia of Georgia Center for Bleeding and Clotting Disorders of CHOA, Atlanta, Georgia, USA.
Research and practice in thrombosis and haemostasis
|August 14, 2025
概括
激活前列红素复合物缩剂 (aPCC) 是安全的管理出血在血友病A患者在埃米齐祖马布预防. 新出现的数据显示,aPCC在≤100U/kg/天时的血栓事件没有增加,支持其与其他非因子疗法一起使用.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 非因子疗法 (NFTs) 像埃米齐祖马布越来越多地用于血友病A的预防.
- 管理NFT患者的突破性出血,特别是那些使用抑制剂的患者,需要有效的绕过剂 (BPA).
- 早期对埃米齐祖马布的血栓事件的担忧导致了指导方针偏好复合激活因子VII (rFVIIa) 而不是激活前列血复合物缩物 (aPCC).
研究的目的:
- 审查aPCC在血友病A患者的出血管理中的安全性和疗效的证据,这些患者接受艾米齐祖马布或其他NFT的抑制剂.
- 为了评估与aPCC在这个特定患者群体中使用相关的血栓事件的风险.
主要方法:
- 临床和现实研究的叙述性综述.
- 使用aPCC在A型血友病患者和NFT预防中的抑制剂治疗出血管理数据的评估.
主要成果:
- 新出现的数据表明,aPCC在剂量≤100U/kg/day时,与患者的血栓性微血管病变或血栓性事件无关.
- 这些发现挑战了早期的指导方针,这些指导方针更喜欢rFVIIa而不是aPCC来管理突破性出血.
结论:
- aPCC是一种可行且安全的选择,用于管理患有血友病A型患者的出血,这些患者使用制剂进行埃米齐祖马布的预防.
- 随着越来越多的NFT变得可用,aPCC和rFVIIa都将是全面出血管理的必要条件.
- 最佳使用BPA需要了解影响选择的因素,包括出血特征,临床反应和患者偏好.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
903
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
903
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:26EDTA: Auxiliary Complexing Reagents
672
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
672
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44